Pharmacokinetic and Safety Equivalence Demonstrated Between HD204, a Biosimilar of Bevacizumab, in Healthy Male Subjects

2020 Year in Review - Biosimilars - Biosimilars

The results of a phase 1 pharmacokinetic and safety equivalence study demonstrated equivalence between HD204 and both bevacizumab-EU and bevacizumab-US in healthy males.

A single-blind, single-dose, randomized, 3-arm, parallel-group phase 1 study (SAMSON) was conducted to confirm pharmacokinetic and safety equivalence between bevacizumab and HD204, a candidate biosimilar to bevacizumab, in healthy males. These results were reported at the 2020 American Society of Clinical Oncology Virtual Scientific Program.

A total of 120 healthy males were included in the study. Enrolled subjects were randomized 1:1:1 to receive either HD204, bevacizumab licensed in the European Union (bevacizumab-EU), or bevacizumab approved in the United States (bevacizumab-US) at a dose of 1 mg/kg administered by intravenous infusion. Comparative assessments included pharmacokinetic parameters, safety, including adverse events, incidence of antidrug antibodies, and neutralizing antibodies.

Pharmacokinetic equivalence was established between HD204 and both bevacizumab-EU and bevacizumab-US, based on comparable results from pairwise comparisons of pharmacokinetic parameters, including exposure (area under the plasma drug concentration–time curve [AUC] to infinity and AUC up to the last quantifiable time point), maximal concentration, half-life, clearance, and volume of distribution. Treatment-related adverse events were comparable between HD204 and the 2 bevacizumab reference groups; the incidence of treatment-related adverse events was 25.0% in HD204 group, 30.0% in the bevacizumab-EU group, and 25.6% in the bevacizumab-US group. There were no treatment-emergent serious adverse events. In terms of immunogenicity, subjects who received HD204 did not develop antidrug antibodies.

Based on these results, it was concluded that HD204 demonstrated equivalence to both bevacizumab-EU and bevacizumab-US in terms of pharmacokinetics and safety in healthy male subjects.

Reference
Hii J, et al. ASCO 2020. Abstract e21556.

Related Items
Adoption of Biosimilars—Why the Delay?
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Editorial, Biosimilars
Pharmacist-Driven Intervention Significantly Increases Biosimilar Adoption in Clinical Practice
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Biosimilars, Oncology Pharmacy Programs, ASCO Highlights
Comparing Single-Center Outcomes Between Reference and Biosimilar Granulocyte Colony-Stimulating Factor Drugs Used for Autologous Stem-Cell Mobilization
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Original Article, Biosimilars, Transplant
Oncologists’ Common Misconceptions About Biosimilars Revealed in a Recent Survey
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Biosimilars, ASCO Highlights
Comparative Efficacy and Safety of the Bevacizumab Biosimilar MIL60 versus Bevacizumab Reference in Patients with Advanced or Recurrent Nonsquamous NSCLC
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Same-Day Pegfilgrastim or PFG-cbqv Prophylaxis of Chemotherapy-Induced Neutropenia in Bendamustine plus Rituximab and CHOP±R Regimens in Patients with Lymphoma and CLL
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Same-Day Pegfilgrastim or Pegfilgrastim-cbqv Prophylaxis in miniCHOP Chemotherapy-Based Regimens for Non-Hodgkin Lymphoma
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Demographics and Clinical Characteristics of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-awwb in Real-World Oncology Clinics
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Impact of the Oncology Care Model on Use of Bone Supportive Medications, Antiemetics, and Growth Factors
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
Cost-Efficiency Analysis of Conversion from Pegfilgrastim with On-Body Injector to Pegfilgrastim-jmdb to Provide Budget-Neutral Expanded Access to Prophylaxis and Treatment
2021 Year in Review - Biosimilars published on December 31, 2021 in Biosimilars
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: